Tenaya Therapeutics, Inc. (TNYA)

Market: NASD | Currency: USD

Address: 171 Oyster Point Boulevard

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf Show more

📈 Tenaya Therapeutics, Inc. Historical Chart

📊 Statistics

Analyst 1 Year Price Target: $10.14
Upside/Downside from Analyst Target: 1,653.30%
Broker Call: 18
Dividend Minimum 3 Year Yield: 0.00%
EPS Growth Range (1Y): 25-50%
Net Income Growth Range (1Y): 10-25%
Revenue Growth Range (1Y): -

💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for Tenaya Therapeutics, Inc.

Date	Reported EPS
2025-05-07	-0.24
2025-03-10	-0.28
2024-11-06	-0.3
2024-08-08	-0.34
2024-08-07	-0.34
2024-05-14	-0.4
2024-05-13	-0.4
2024-03-18	-0.4
2024-03-17	-0.4
2023-11-08	-0.39
2023-11-07	-0.39
2023-08-09	-0.45
2023-08-08	-0.45
2023-05-10	-0.43
2023-05-09	-0.43
2023-03-08	-0.61
2023-03-07	-0.61
2022-11-10	-0.74
2022-11-09	-0.74
2022-08-10	-0.69
2022-08-09	-0.69
2022-05-11	-0.75
2022-05-10	-0.75
2022-03-23	-0.63
2022-03-22	-0.63
2021-11-10	-0.68
2021-11-09	-0.68
2021-09-08	-13.26
2021-09-07	-13.26
2021-07-30	-
2021-07-29	-

📰 Related News & Research

No related articles found for "tenaya therapeutics".